Ros1derings : August Edition


The second issue of our newsletter was released just over two weeks ago. For those who have missed it, you can grab it here : Ros1derings : August edition Contents include: A feature about Luna Okada, a 6.5 year ROS1der Some numbers about Xalkori use Fundraising updates Tips for traveling with stage 4 cancer An … Continue reading Ros1derings : August Edition

Entrectinib -Roche’s Gene-Targeting Drug Shows Promise in Child Brain Tumors


“The young boy was running out of time. His brain tumor was growing so fast that he had trouble putting words together. All standard cancer treatments had failed. Then last summer the child started taking an experimental pill that targeted a rare genetic mutation found inside his tumor. Within months, the malignant growth started to … Continue reading Entrectinib -Roche’s Gene-Targeting Drug Shows Promise in Child Brain Tumors

Announcing The ROS1ders newsletter “ROS1derings”


We’ve created a newsletter! This newsletter will become a quarterly communication tool for The ROS1ders. In this issue, Marisa Wittebort shares tips for contributing to the ROS1 tissue study, Bärbel Söhlke​ writes about ROS1 activities in Europe, Jeff Wynne details what his data base shows about ROS1 members, and Lisa Goldman offers a fundraising update. … Continue reading Announcing The ROS1ders newsletter “ROS1derings”

Advocating for ROS1


One of the founders of the ROS1ders, Janet Freeman-Daily, shares her story and why she advocates for molecular testing, clinical trials, and the positive changes she’s seen. “Given that lung cancer patients often don’t have much tumor tissue, we should make the best use of it, and running an NGS test is the best chance … Continue reading Advocating for ROS1

Crizotinib approved for ROS1 in Australia


“From 1 January the medicine Xalkori® (crizotinib) will made available through the Pharmaceutical Benefits Scheme (PBS) for lung cancer patients with a c-ROS proto-oncogene 1 (ROS1) gene rearrangement. The drug may stop or slow the growth of Stage IIIB (locally advanced) or Stage IV (metastatic) non-small cell lung cancer. Without the PBS subsidy the drug … Continue reading Crizotinib approved for ROS1 in Australia

U.S. FDA Approves LORBRENA® (lorlatinib) for Previously-Treated ALK-Positive Metastatic NSCLC


“Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved LORBRENA® [lor-BREN-ah] (lorlatinib), a third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or … Continue reading U.S. FDA Approves LORBRENA® (lorlatinib) for Previously-Treated ALK-Positive Metastatic NSCLC